17 results about "Excitotoxicity" patented technology

The application discloses a prenylated polyketide compound, a preparation method and application thereof, and the prenylated polyketide compound is separated from rice fermented with Xylaria nigriplicata. The neuroprotective effect of the prenylated polyketide compound on glutamate-induced excitotoxicity of PC12 cells is clarified through comprehensive evaluation of cell viability, apoptosis and key oxidative stress markers.

Antisense oligonucleotides are provided which target potassium channel tetramerization domain containing 20 (KCTD20) and can be used in treating, inhibiting, or reducing the severity of a neurodegenerative disease, especially those involving glutamate excitotoxicity.

The present invention relates to use of biopterin compounds such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin or 4-Amino-(6R,S)-7,8-dihydro-L-biopterin for treating a human patient suffering from a disease condition or disorder that is associated with an increased glutamate level. The invention also relates to the use of such biopterin compounds in a method of treating or preventing glutamate excitotoxicity (glutamate storm) in a patient suffering from a condition that has the potential to result in a pathologically high glutamate level in the brain.

The invention provides an umami peptide without nervous excitatory toxicity and a preparation process and application thereof, the umami peptide is extracted from broad bean protein, and the amino acid sequence is shown as SEQ ID NO.1 and / or SEQ ID NO.2. Compared with a traditional umami substance-sodium glutamate (monosodium glutamate MSG), the umami peptide has the characteristics of activating umami receptors TAS1R1 / TAS1R3 without acting on sodium glutamate receptors such as NMDA and the like, and has the advantages that the umami peptide can be used for preparing the umami peptide. No NMDA receptor mediated excitatory neurotoxicity exists; meanwhile, the umami peptide can stimulate intestinal endocrine cells (STC-1) to secrete GLP-1.

This invention belongs to the field of pharmaceutical technology, specifically relating to a novel tannin derivative isolated for the first time from *Cotinus coggygria*, its preparation method, and its pharmaceutical uses. This compound exhibits significant neuroprotective activity, counteracting glutamate-induced excitotoxic damage and inhibiting TNF-α-mediated neuroinflammatory responses. It can be used to prepare drugs for the prevention or treatment of neurological diseases involving excitotoxicity and / or neuroinflammatory disorders. Formula (I)

The present invention relates to modulators of canonical-type of transient receptor potential (TRPC) channels, compositions thereof, and methods therewith. The present invention also relates to methods of treating TRPC mediated conditions using such modulators.

This invention discloses an extracellular vesicle derived from Gastrodia elata, its preparation method, and its use in preparing drugs for treating glaucoma, belonging to the field of biomedical technology. This invention claims protection for an extracellular vesicle prepared from dried Gastrodia elata. The extracellular vesicles provided by this invention have no significant cytotoxicity and good biocompatibility. Studies have shown that these extracellular vesicles can significantly inhibit apoptosis of R28 cells and loss of Brn3a⁺ cells in the mouse retina in a glutamate excitotoxicity model. In a glaucoma model, these extracellular vesicles can effectively protect the survival of retinal ganglion cells (RGCs) and retinal function, and can significantly reduce retinal neuroinflammatory responses in the glaucoma model. Therefore, the extracellular vesicles provided by this invention have a clear anti-glaucoma-related retinal damage effect and possess great potential for development into drugs for treating glaucoma.

A method for ameliorating a disease caused by nitration of tyrosine in protein includes administering a composition comprising tyrosine or a salt thereof to a subject in need thereof. Tyrosine as effective component of the present invention not only can enhance the activity of glutamine synthetase having reduced activity and but also has an effect of restoring the amount (i.e., ratio) of glutamine and glutamic acid in brain and the amount of ammonia to normal level, an effect of enhancing the insulin sensitivity in a model of type 2 diabetes, an effect of suppressing the excitotoxicity and oxidative stress in a model of epileptic seizure, an effect of reducing cerebral infarction and enhancing the activity of GS in a model of brain stroke, an effect of eliminating the nitration of tyrosine using human recombinant MnSOD, and an effect for acute renal failure and hyperammonemia.

The invention relates to a multi-target quinazolinone derivative as well as a synthesis method and application thereof. Specifically, the invention relates to a quinazolinone compound with a structure as shown in a formula I. Each substituent group is defined in the specification. The quinazolinone compound disclosed by the invention plays a role in preventing and treating cerebral apoplexy by inhibiting oxidative stress, excitatory injury and inflammatory response.

The invention belongs to the technical field of biological medicines, and relates to a bionic nano-enzyme composition for inhibiting ferroptosis and relieving excitatory toxicity as well as preparation and application of the bionic nano-enzyme composition. The biomimetic nano-enzyme composition disclosed by the invention consists of platinum nano-enzyme and lactoferrin, and can effectively relieve cerebral ischemia-reperfusion injury and play a role in neuroprotection by inhibiting ferroptosis and relieving excitatory toxicity. The biomimetic nano-enzyme composition disclosed by the invention can be used for remarkably enhancing active oxygen removal and inflammation regulation capabilities of platinum nano-enzyme as well as in-vivo brain targeting and permeability, and finally, the treatment effect on cerebral ischemia reperfusion injury is effectively improved. The biomimetic nano-enzyme composition disclosed by the invention combines active oxygen and ammonium ion removal activity of platinum nano-enzyme and iron chelation and brain targeting capabilities of lactoferrin, realizes multi-target and multi-path treatment, and effectively improves the treatment effect of cerebral ischemia-reperfusion injury.

The present invention is directed to the treatment of obsessive-compulsive disorder (OCD) and OCD-related disorders (including body dysmorphic disorder, hoarding disorder, trichotillomania (hair pulling disorder), skin picking disorder, substance / medication-induced obsessive-compulsive disorder and related disorders, obsessive-compulsive disorder and related disorders due to another medical condition, and other specified and unspecified obsessive-compulsive disorder and related disorders), tic disorders including Tourette's syndrome, autism spectrum disorder (ASD), and amyotrophic lateral sclerosis (ALS), Parkinson's disease, traumatic brain injury, Provided is a method for treating glutamate excitotoxicity-related disorders, including multiple sclerosis, Huntington's disease, and schizophrenia, comprising administering an effective amount of a histamine type 1 receptor agonist and / or a histamine type 3 receptor antagonist, such as betahistine or a pharmaceutically acceptable salt, analog, metabolite, prodrug, derivative, metabolite, cocrystal, modification, solvate, hydrate, isotope, tautomer, ester, polymorph, or stereoisomer thereof.

Provided are methods of treating neuropsychiatric disorders including obsessive-compulsive related disorders, tic disorders, glutamate excitotoxicity related disorders, autism spectrum disorders, and other medical conditions in patients with a mutation in genes involving function, structure, or plasticity, including but not limited to SHANK3, SAPAP3, NLGN3, NLGN4, NRXN1, CNTNAP2, or MECP2. The methods include administering an effective amount of a histamine type 1 receptor agonist and / or histamine type 3 receptor antagonist or inverse agonist, their pharmaceutically acceptable salts, analogs, metabolites, and prodrugs, including prodrugs of its metabolites, to patients in need of such treatment.

The invention discloses an ion-immune-electric coupling 3D bionic conductive catheter and a preparation method and application thereof, and belongs to the technical field of biomedical materials. According to the catheter, a gelatin / poly-L-lactic acid / polypyrrole nanofiber scaffold serves as a substrate, tannic acid and magnesium ions are loaded in sequence, and a three-dimensional bionic structure with electrical conductivity, ion slow release and immunoregulation functions is formed. The conductivity of the catheter is matched with that of the natural spinal cord, Mg can be continuously released to reduce excitatory toxicity of neurons, and macrophages are synergistically regulated and controlled to be polarized to M2 phenotype through tannic acid, so that oxidative stress and inflammation are relieved. In-vitro experiments show that the catheter can promote neural stem cells to differentiate into neurons and inhibit activation of astrocytes. In a rat full-cross-section spinal cord injury model, when the catheter is implanted, axon regeneration, myelin sheath formation and synaptic occurrence can be remarkably promoted, movement and urinary function recovery are effectively improved, and an innovative treatment strategy is provided for spinal cord injury repair.

The present invention provides methods for treating obsessive-compulsive disorder (OCD) and OCD-related disorders (somatic deformation disorder, hoarding disorder, depilation disorder), scratch (skin scratching) disorder, substance / drug induced obsessive-compulsive disorder and related disorders, obsessive-compulsive disorder and related disorders caused by another medical condition, and OCD-related disorders. And other specified and unspecified obsessive-compulsive disorders and related disorders); a twitch disorder, including Tourette Syndrome; autism spectrum disorder (ASD); and glutamate excitatory toxicity related disorders, including amyotrophic lateral sclerosis (ALS); parkinson's disease; traumatic brain injury; multiple sclerosis; huntington's disease; and schizophrenia, the method comprising administering an effective amount of a histamine type 1 receptor agonist and / or a histamine type 3 receptor antagonist, the invention also relates to a preparation method of the compound, such as betahistine or pharmaceutically acceptable salts, analogs, metabolites, prodrugs, derivatives, metabolites, co-crystals, modifiers, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers thereof.

The present invention relates to modulators of canonical-type of transient receptor potential (TRPC) channels, compositions thereof, and methods therewith. The present invention also relates to methods of treating TRPC mediated conditions using such modulators.

This invention relates to the field of pharmaceutical technology, specifically to a perioperative neuroprotective anesthetic composition and its application for ischemic stroke. The composition comprises the active ingredient remimazolam or a pharmaceutically acceptable salt thereof, MCC950, TRO19622, levamisole or a pharmaceutically acceptable salt thereof, lipoic acid, and a pharmaceutically acceptable carrier, with each active ingredient formulated in a specific molar ratio. This composition combines stable and controllable anesthetic effects with multi-target synergistic neuroprotective effects, adapting to the entire perioperative anesthesia needs for ischemic stroke. Through upstream and downstream synergistic inhibition of mitochondrial damage and the NLRP3 pyroptosis pathway, dual regulation of perioperative sympathetic tone to stabilize cerebral perfusion, synergistic reduction of glutamate excitotoxicity, and enhancement of endogenous antioxidant defense, it comprehensively blocks the core links of perioperative ischemia-reperfusion brain injury, significantly reducing the risk of postoperative neurological deficits and cognitive impairment. It exhibits excellent circulatory and respiratory safety, rapid awakening without affecting early postoperative neurological function assessment.

The present invention provides for methods of treating obsessive-compulsive disorder (OCD) and OCD-related disorders (body dysmorphic disorder, hoarding disorder, trichotillomania (hair-pulling disorder), excoriation (skin-picking) disorder, substance / medication-induced obsessive-compulsive and related disorder, obsessive- compulsive and related disorder due to another medical condition, and other specified and unspecified obsessive-compulsive and related disorders), Tic disorders including Tourette syndrome, autism spectrum disorder (ASD) and glutamate excitotoxicity related disorders including amyotrophic lateral sclerosis (ALS), Parkinson's disease, traumatic brain injury, multiple sclerosis, Huntington's disease, and schizophrenia, comprising the step of administering an effective amount of a histamine type 1 receptor agonist and / or histamine type 3 receptor antagonist, such as betahistine or its pharmaceutically acceptable salts, analogs, metabolites, prodrugs, derivatives, metabolites, co-crystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers.